Dyax market cap tops $3.5B on DX-2930 news

Dyax Corp. (NASDAQ:DYAX) gained $9 (54%) to $25.75 on Wednesday following postmarket data Tuesday that showed DX-2930 significantly reduced hereditary angioedema (HAE) attacks in a Phase Ib trial and received Fast Track designation from FDA. Dyax ended Wednesday with a market cap of $3.5 billion. ...